InvVax, Inc. is focused on developing next-generation vaccines, with an initial emphasis on influenza. The company utilizes a patented universal advanced vaccine technology that was discovered at UCLA. This innovative approach aims to create vaccines that not only address current health challenges but also have the potential to prevent future pandemics. By thinking outside the box, InvVax is positioning itself as a leader in the vaccine development space, leveraging its proprietary methods to enhance vaccine efficacy and broaden their applicability.

The company's strategy revolves around breakthrough and patented vaccine technologies that promise to revolutionize the way vaccines are developed and administered. InvVax's commitment to advancing vaccine science is evident in its rigorous testing and development processes, which are designed to ensure the safety and effectiveness of its products. Through its unique approach, InvVax aims to contribute significantly to public health by providing innovative solutions that can adapt to emerging infectious diseases.

United States

InvVax was incorporated in January 2013. Located in sunny Southern California, it maintains a strong affiliation with the UCLA, where its technology was originally developed. InvVax has access to a wide network of leading investigators in diverse disciplines, including molecular virology, immunology, pharmacology, and clinical infectious diseases.



InvVax, Inc

Company Details